Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, has announced that the 2-year R&D collaboration with Roche concerning ORY-1001, licensed to Roche in 2014, has been extended until March 2017.
ORY-1001 (RG6016) is a highly potent and selective inhibitor of LSD1 currently in Phase I/IIA in acute leukaemia patients. The license agreement by which the development and commercial rights to ORY-1001 were granted to Roche, included a 2-year collaborative research programme between Oryzon and Roche to further explore the potential of ORY-1001 in oncology and haematology.
The programme has delivered additional insight into the drug’s mechanism of action, provided support for its use in indications beyond acute leukaemia and has expanded the toolbox for future and current clinical trials. Oryzon will continue to support the development of ORY-1001 through an extension of the collaborative research programme that will run until March 2017 with the main goal to finalize the transfer of the newly generated technology and knowledge.
Carlos Buesa, Oryzon’s CEO, has declared: “This collaboration between Roche and Oryzon has been highly satisfactory and the success of the collaboration is reflected in four newly filed patent applications. We have been impressed by the experience of our partner and are convinced the results generated will strengthen the further clinical development of ORY-1001.”